Innovative Approaches for the Treatment of Nucleotide Repeat Expansion Disorders

AstraZeneca, a global biopharmaceutical and biotechnology company, is looking to collaboratively uncover and advance groundbreaking approaches for mitigating nucleotide repeat expansion toxicity.

While the association between nucleotide repeat expansion toxicity and muscle and CNS disorders is well-established, current strategies face challenges in effectively mitigating the toxicity.

AstraZeneca is seeking innovative strategies or novel concepts for mitigating nucleotide repeat expansion toxicity, with the potential to be applied in the treatment of muscle or CNS diseases.

Submission Information

Applicants should complete the proposal form which should contain a brief, non‑confidential overview of your proposal, including a workplan, approximate budgetary requirements, desired outcomes, and background on your research group. To submit your proposal, please visit the Inpart website, register, and submit your application form under the appropriate campaign.

Programme Information

AstraZeneca’s CoSolve challenge is an annual, global Open Innovation programme seeking collaborators with innovative solutions to real research challenges. These challenges lie within the company’s R&D research focus areas and require solutions that are immediately translatable. Collaborators are sought who can bring innovative ideas that can be rapidly translated into tangible solutions. Working together, these ideas could help shape the development and delivery of new therapies and bring them to patients sooner.

Opportunity for Collaboration

Applications that are of interest will be selected to participate in the virtual Challenge Week - an intensive week where applicants will pitch their ideas and work with AstraZeneca scientists to transform their idea into a workplan. For selected winners from the challenge week, a collaboration agreement will be put in place with specified milestones and the winning projects can begin quickly.